ASGR1 and neoplasm: Chen et al. (2017) found that dual-targeted CAR-T cells co-expressing complementary GPC3 and asialoglycoprotein receptor 1 (a liver tissue-specific protein)-targeted CARs showed relatively potent anti-tumor activity against HCC tumor xenografts with double antigens, but exhibited the restricted antitumor activity against HCC xenografts with a single antigen, indicating that dual-targeted CAR-T cells could be a promising strategy for reducing or avoiding the potential off-tumor toxicities of the GPC3-CAR T cell therapy on HCC.